Genovate Biotechnology
4130 · TPEx
Assets
(2 total)
2Total Assets
0Approved
2Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Phosphodiesterase 3 (PDE3)Small molecule | Atherosclerotic Cardiovascular Disease | |
Prusogliptin(Shanzeping) | Phase 3 | DPP-4Small molecule | Type 2 Diabetes |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
28 May 2024Topline resultPMR (cilostazol ER)GBL23-001 (NCT06167265) bioequivalence study met its primary endpoints; NDA planned for the second half of 2025
US · Genovate Biotechnology Co., Ltd. · Source ↗
Financial reports
No financial reports recorded.